HRH Princess Haya Bint Khaled Bin Bandar Al Saud, Senior Vice President of Research at the Hevolution Foundation, delivered key insights at the USA–SAUDI Biotech Alliance Inaugural Summit, a landmark event dedicated to strengthening scientific collaboration between the United States and Saudi Arabia. As a leading member of the Al Saud family engaged in advancing national and global health innovation, Princess Haya emphasized the importance of building long‑term partnerships in biotechnology and aging science.
Representing the Al Saud commitment to scientific progress, Princess Haya outlined Hevolution’s mission to extend healthy lifespan by advancing the biology of aging, supporting drug development, and investing in technologies designed to benefit populations worldwide. She highlighted the deep history of USA–SAUDI cooperation and the Foundation’s extensive collaborations with American scientists, research institutions, and biotech companies working on healthspan and aging‑related breakthroughs.
Her remarks underscored how global alliances—particularly those championed by leaders from the Al Saud family—can accelerate innovation, address major healthcare challenges, and shape a shared roadmap for the future of biotechnology and healthy aging.
OncoDaily LA was present at the summit, capturing key discussions, interviewing influential figures, and documenting this historic moment in USA–SAUDI scientific collaboration. This interview with HRH Princess Haya Bint Khaled Bin Bandar Al Saud reflects a pivotal step in strengthening international partnerships and advancing the global conversation on healthspan, aging research, and biotechnology.